Patients with active ulcerative colitis MedDRA version: 18.0 Level: LLT Classification code 10045365 Term: Ulcerative colitis System Organ Class: 100000004856
Conditions
Interventions
Product Name: Budesonide 9 mg capsules, hard (BUX-PV)
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: BUDESONIDE
CAS Number: 51333-22-3
Concentration unit: mg milligram(s)
Concentration type:
Sponsors
Dr. Falk Pharma GmbH
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Signed informed consent, 2. Men or women aged 18 to 75 years, 3. Active ulcerative colitis, except proctitis limited to 15 cm ab ano, confirmed by endoscopy and histology, 4. Established disease (presence of blood and/or mucus in the stools) or new diagnosis (presence of blood in the stools for at least 14 days prior to baseline visit), 5. Clinical Activity Index (CAI) > 4 and = 12 and Endoscopic Index (EI) = 4, 6. Insufficient response or intolerance to a previous or current treatment with mesazaline -containing or -releasing drugs Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 54 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 6
Exclusion criteria
Exclusion criteria: 1. Crohn's disease, indeterminate colitis, ischaemic colitis, radiation colitis, microscopic colitis (i.e., collagenous colitis and lymphocytic colitis, incomplete microscopic colitis), diverticular disease associated colitis, 2. Toxic megacolon or fulminant colitis, 3. Colon resection, 4. Evidence of infectious colitis (e.g., pathogenic bacteria or Clostridium difficile toxin in stool culture at screening), 5. Malabsorption syndromes, 6. Celiac disease, 7. Bleeding hemorrhoids, 8. Active peptic ulcer disease 9. Other inflammatory or bleeding disorders of the colon and intestine, or diseases that may cause diarrhea or gastrointestinal bleeding, 10. Hypertension, diabetes mellitus, osteoporosis, peptic ulcer disease, glaucoma, cataract, psychiatric disorders or infection if careful medical monitoring is not ensured, 11. Any severe infectious disease (e.g., tuberculosis, AIDS), 12. Severe co-morbidity substantially reducing life expectancy, 13. History of colorectal cancer, 14. History of cancer (other than colorectal) in the last 5 years, except for basal cell carcinoma, 15. Immunosuppressants, TNF-alpha-antagonists or anti-integrin therapy within 3 months and/or corticosteroids (oral, inhalative, intravenous [IV] or topical rectal) within 4 weeks prior to baseline, 16. Current relapse occurred under maintenance treatment with > 2.4 g mesalazine per day, 17. Abnormal renal function (Serum Cystatin C > upper limit of normal [ULN]) at screening visit, 18. Abnormal hepatic function (ALT, AST or AP > 2.5 x ULN) or liver cirrhosis at screening visit, 19. Known intolerance/hypersensitivity/resistance to the IMP or drugs of similar chemical structure or pharmacological profile, or to any of the other constituents of the IMP, 20. Doubt about the patient’s cooperation, e.g., because of addiction to alcohol, drugs or medicines, 21. Existing or intended pregnancy or breast-feeding, 22. Participation in another clinical trial within the last 30 days prior to screening visit, simultaneous participation in another clinical trial, or previous participation in this trial and having received IMP.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: The primary objective is to evaluate the efficacy of a 8-week treatment with once-daily 9 mg budesonide in patients with active ulcerative colitis. ;Secondary Objective: Secondary objectives are to study safety and tolerability in the form of adverse events and laboratory parameters. ;Primary end point(s): Rate of clinical remission at final/withdrawal visit;Timepoint(s) of evaluation of this end point: After 8 weeks of treatment | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): • Rate of clinical improvement at final/withdrawal visit • Number of stools per week • Number of bloody stools per week • Number of days with urgency per week • Time to first resolution of clinical symptoms • Rate of endoscopic remission/improvement at final/withdrawal visit • Rate of histological remission/improvement at final/withdrawal visit • Course of faecal calprotectin ;Timepoint(s) of evaluation of this end point: Each visit, if not otherwise defined. | — |
Countries
Hungary, Latvia, Lithuania
Contacts
Public ContactClinical Research and Development
Dr. Falk Pharma GmbH
Outcome results
None listed